GLAXF - Gritstone Poised To Dominate mRNA Market

• Gilead Sciences and Gritstone bio have a collaboration on a vaccine platform for curing HIV. Gilead has already paid $30 million upfront and bought $35 million in stock.
• Gritstone bio recently completed a $55 million PIPE with leading life sciences investors Frazier Life Sciences, Redmile Group, and Gilead Sciences.
• Gritstone announced groundbreaking early-stage clinical data at ESMO 2021 from their personalized immunotherapy program GRANITE for microsatellite stable colorectal cancer; pivotal trial to start soon.
• The company has multiple ongoing trials that are evaluating self-amplifying mRNA as next-gen vaccine technology to combat COVID-19.
• GRTS recently dosed the first solid tumor patient in Phase 2 clinical trials studying an optimized SLATE v2 cassette of their  “Off-the-Shelf” immunotherapy.

For further details see: